---
document_datetime: 2025-11-23 08:01:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/imatinib-koanaa.html
document_name: imatinib-koanaa.html
version: success
processing_time: 0.1063613
conversion_datetime: 2025-12-24 20:56:19.445138
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Imatinib Koanaa

[RSS](/en/individual-human-medicine.xml/67475)

##### Withdrawn

This medicine's authorisation has been withdrawn

imatinib

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Imatinib Koanaa](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 31 August 2023, the European Commission withdrew the marketing authorisation for Imatinib Koanaa (imatinib) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Koanaa Healthcare GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Imatinib Koanaa was granted marketing authorisation in the EU on 22 September 2021 for the treatment of adults and children with:

- chronic myeloid leukaemia (CML), in patients who are 'Philadelphia chromosome positive' (Ph+),
- Ph+ acute lymphoblastic leukaemia (ALL).

This medicine is also used for treating adults with:

- myelodysplastic or myeloproliferative diseases (MD/MPD),
- advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL),
- gastrointestinal stromal tumours (GIST),
- dermatofibrosarcoma protuberans (DFSP).

The marketing authorisation was initially valid for a 5-year period.

Imatinib Koanaa is a generic medicine of Glivec. There are other generic medicinal products of Glivec authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Imatinib Koanaa is updated to indicate that the marketing authorisation is no longer valid.

Imatinib Koanaa : EPAR - Medicine overview

Reference Number: EMA/429510/2021

English (EN) (299.7 KB - PDF)

**First published:** 01/10/2021

**Last updated:** 19/10/2023

[View](/en/documents/overview/imatinib-koanaa-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-739)

български (BG) (334.56 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/bg/documents/overview/imatinib-koanaa-epar-medicine-overview_bg.pdf)

español (ES) (277.91 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/es/documents/overview/imatinib-koanaa-epar-medicine-overview_es.pdf)

čeština (CS) (316.51 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/cs/documents/overview/imatinib-koanaa-epar-medicine-overview_cs.pdf)

dansk (DA) (274.08 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/da/documents/overview/imatinib-koanaa-epar-medicine-overview_da.pdf)

Deutsch (DE) (283.04 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/de/documents/overview/imatinib-koanaa-epar-medicine-overview_de.pdf)

eesti keel (ET) (259.82 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/et/documents/overview/imatinib-koanaa-epar-medicine-overview_et.pdf)

ελληνικά (EL) (339.95 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/el/documents/overview/imatinib-koanaa-epar-medicine-overview_el.pdf)

français (FR) (281.11 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/fr/documents/overview/imatinib-koanaa-epar-medicine-overview_fr.pdf)

hrvatski (HR) (298.87 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/hr/documents/overview/imatinib-koanaa-epar-medicine-overview_hr.pdf)

italiano (IT) (268.75 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/it/documents/overview/imatinib-koanaa-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (310.4 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/lv/documents/overview/imatinib-koanaa-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (304.46 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/lt/documents/overview/imatinib-koanaa-epar-medicine-overview_lt.pdf)

magyar (HU) (298.65 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/hu/documents/overview/imatinib-koanaa-epar-medicine-overview_hu.pdf)

Malti (MT) (318.42 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/mt/documents/overview/imatinib-koanaa-epar-medicine-overview_mt.pdf)

Nederlands (NL) (283.87 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/nl/documents/overview/imatinib-koanaa-epar-medicine-overview_nl.pdf)

polski (PL) (309.47 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/pl/documents/overview/imatinib-koanaa-epar-medicine-overview_pl.pdf)

português (PT) (278.04 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/pt/documents/overview/imatinib-koanaa-epar-medicine-overview_pt.pdf)

română (RO) (311.14 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/ro/documents/overview/imatinib-koanaa-epar-medicine-overview_ro.pdf)

slovenčina (SK) (306.15 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/sk/documents/overview/imatinib-koanaa-epar-medicine-overview_sk.pdf)

slovenščina (SL) (300.06 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/sl/documents/overview/imatinib-koanaa-epar-medicine-overview_sl.pdf)

Suomi (FI) (267.73 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/fi/documents/overview/imatinib-koanaa-epar-medicine-overview_fi.pdf)

svenska (SV) (269.75 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/sv/documents/overview/imatinib-koanaa-epar-medicine-overview_sv.pdf)

Imatinib Koanaa : EPAR - Risk-management-plan summary

English (EN) (281.13 KB - PDF)

**First published:** 01/10/2021

**Last updated:** 19/10/2023

[View](/en/documents/rmp-summary/imatinib-koanaa-epar-risk-management-plan-summary_en.pdf)

## Product information

Imatinib Koanaa : EPAR - Product information

English (EN) (2.69 MB - PDF)

**First published:** 01/10/2021

**Last updated:** 19/10/2023

[View](/en/documents/product-information/imatinib-koanaa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-869)

български (BG) (16.64 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/bg/documents/product-information/imatinib-koanaa-epar-product-information_bg.pdf)

español (ES) (15.82 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/es/documents/product-information/imatinib-koanaa-epar-product-information_es.pdf)

čeština (CS) (13.77 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/cs/documents/product-information/imatinib-koanaa-epar-product-information_cs.pdf)

dansk (DA) (16.56 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/da/documents/product-information/imatinib-koanaa-epar-product-information_da.pdf)

Deutsch (DE) (18.84 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/de/documents/product-information/imatinib-koanaa-epar-product-information_de.pdf)

eesti keel (ET) (10.35 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/et/documents/product-information/imatinib-koanaa-epar-product-information_et.pdf)

ελληνικά (EL) (19.49 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/el/documents/product-information/imatinib-koanaa-epar-product-information_el.pdf)

français (FR) (19.08 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/fr/documents/product-information/imatinib-koanaa-epar-product-information_fr.pdf)

hrvatski (HR) (9.75 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/hr/documents/product-information/imatinib-koanaa-epar-product-information_hr.pdf)

íslenska (IS) (16.13 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/is/documents/product-information/imatinib-koanaa-epar-product-information_is.pdf)

italiano (IT) (2.8 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/it/documents/product-information/imatinib-koanaa-epar-product-information_it.pdf)

latviešu valoda (LV) (3.04 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/lv/documents/product-information/imatinib-koanaa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (16.35 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/lt/documents/product-information/imatinib-koanaa-epar-product-information_lt.pdf)

magyar (HU) (16.86 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/hu/documents/product-information/imatinib-koanaa-epar-product-information_hu.pdf)

Malti (MT) (11.04 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/mt/documents/product-information/imatinib-koanaa-epar-product-information_mt.pdf)

Nederlands (NL) (15.67 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/nl/documents/product-information/imatinib-koanaa-epar-product-information_nl.pdf)

norsk (NO) (16.43 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/no/documents/product-information/imatinib-koanaa-epar-product-information_no.pdf)

polski (PL) (6.83 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/pl/documents/product-information/imatinib-koanaa-epar-product-information_pl.pdf)

português (PT) (10.91 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/pt/documents/product-information/imatinib-koanaa-epar-product-information_pt.pdf)

română (RO) (16.46 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/ro/documents/product-information/imatinib-koanaa-epar-product-information_ro.pdf)

slovenčina (SK) (14.43 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/sk/documents/product-information/imatinib-koanaa-epar-product-information_sk.pdf)

slovenščina (SL) (15.68 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/sl/documents/product-information/imatinib-koanaa-epar-product-information_sl.pdf)

Suomi (FI) (11.16 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/fi/documents/product-information/imatinib-koanaa-epar-product-information_fi.pdf)

svenska (SV) (15.69 MB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/sv/documents/product-information/imatinib-koanaa-epar-product-information_sv.pdf)

22/09/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Imatinib Koanaa : EPAR - All authorised presentations

English (EN) (77.9 KB - PDF)

**First published:** 01/10/2021

**Last updated:** 19/10/2023

[View](/en/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-250)

български (BG) (111.21 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/bg/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_bg.pdf)

español (ES) (97.44 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/es/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (101.62 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/cs/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (98.04 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/da/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (96.37 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/de/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (94.45 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/et/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (106.15 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/el/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_el.pdf)

français (FR) (95.82 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/fr/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (78.48 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/hr/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (100 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/is/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (96.57 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/it/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (100.99 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/lv/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (100.21 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/lt/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (102.3 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/hu/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (103.27 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/mt/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (94.23 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/nl/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (99.61 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/no/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_no.pdf)

polski (PL) (101.8 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/pl/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_pl.pdf)

português (PT) (98.98 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/pt/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_pt.pdf)

română (RO) (100.89 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/ro/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (103.34 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/sk/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (98.58 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/sl/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (94.15 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/fi/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (96.37 KB - PDF)

**First published:**

01/10/2021

**Last updated:**

19/10/2023

[View](/sv/documents/all-authorised-presentations/imatinib-koanaa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Imatinib Koanaa Active substance imatinib mesilate International non-proprietary name (INN) or common name imatinib Therapeutic area (MeSH)

- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Myelodysplastic-Myeloproliferative Diseases
- Hypereosinophilic Syndrome
- Dermatofibrosarcoma
- Gastrointestinal Stromal Tumors

Anatomical therapeutic chemical (ATC) code L01EA01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Imatinib Koanaa is indicated for the treatment of

- adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.
- adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
- adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
- adult patients with relapsed or refractory Ph+ ALL as monotherapy.
- adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
- adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.

The effect of Imatinib on the outcome of bone marrow transplantation has not been determined.

Imatinib Koanaa is indicated for

- the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
- the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.
- the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

In adult and paediatric patients, the effectiveness of Imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

## Authorisation details

EMA product number EMEA/H/C/005595

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Koanaa Healthcare GmbH

Fehrgasse 7

Opinion adopted 22/07/2021 Marketing authorisation issued 22/09/2021 Withdrawal of marketing authorisation 31/08/2023

## Assessment history

## Initial marketing authorisation documents

Imatinib Koanaa : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/444756/2021

English (EN) (2.11 MB - PDF)

**First published:** 01/10/2021

**Last updated:** 19/10/2023

[View](/en/documents/assessment-report/imatinib-koanaa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Imatinib Koanaa

Adopted

Reference Number: EMA/338599/2021

English (EN) (252.31 KB - PDF)

**First published:** 23/07/2021

**Last updated:** 19/10/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-imatinib-koanaa_en.pdf)

#### News on Imatinib Koanaa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 July 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-july-2021) 23/07/2021

**This page was last updated on** 19/10/2023

## Share this page

[Back to top](#main-content)